Treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in people with dementia-related disorders such as Alzheimer’s and…
Articles by Joana Carvalho, PhD
PTI-125, Cassava Sciences’ lead therapeutic candidate for the treatment of Alzheimer’s disease, significantly reduced the levels of…
Scientists have found a series of brain alterations associated with Alzheimer’s disease that occur decades before the onset of the…
The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing…
High blood levels of primary fatty acid amides (PFAMS), a class of fatty molecules involved in sleep and movement…
Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608)…
The combination of two factors, aging and eating foods high in sugar or fats, raises susceptibility to Alzheimer’s disease, a…